Etanercept
Etanercept is a recombinant human receptor fusion protein that suppresses, as a contestant, the interaction of TNF-α with cell surface receptors. It received FDA approval in 1999 to be used in children older than 2 years for the treatment of juvenile idiopathic arthritis. In September 2004, it recei...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-04-01
|
| Series: | Turkderm Turkish Archives of Dermatology and Venereology |
| Subjects: | |
| Online Access: | https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&volume=56&supp=1&Year=2022 |
| _version_ | 1797912511917326336 |
|---|---|
| author | Sibel Alper |
| author_facet | Sibel Alper |
| author_sort | Sibel Alper |
| collection | DOAJ |
| description | Etanercept is a recombinant human receptor fusion protein that suppresses, as a contestant, the interaction of TNF-α with cell surface receptors. It received FDA approval in 1999 to be used in children older than 2 years for the treatment of juvenile idiopathic arthritis. In September 2004, it received approval for the treatment of patients with moderate to severe psoriasis who do not respond to conventional systemic treatments or for whom these therapies are contraindicated or intolerable. |
| first_indexed | 2024-04-10T11:58:16Z |
| format | Article |
| id | doaj.art-6fc557d8a6ef482b93167bae3e535993 |
| institution | Directory Open Access Journal |
| issn | 2651-5164 |
| language | English |
| last_indexed | 2024-04-10T11:58:16Z |
| publishDate | 2022-04-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkderm Turkish Archives of Dermatology and Venereology |
| spelling | doaj.art-6fc557d8a6ef482b93167bae3e5359932023-02-15T16:16:45ZengGalenos Publishing HouseTurkderm Turkish Archives of Dermatology and Venereology2651-51642022-04-0156Suppl 1333610.4274/turkderm.galenos.2022.74429TURKDERM-74429EtanerceptSibel Alper0https://orcid.org/0000-0000-0000-0000Koç University Faculty of Medicine, Department of Dermatology and Venereology, İstanbul, TurkeyEtanercept is a recombinant human receptor fusion protein that suppresses, as a contestant, the interaction of TNF-α with cell surface receptors. It received FDA approval in 1999 to be used in children older than 2 years for the treatment of juvenile idiopathic arthritis. In September 2004, it received approval for the treatment of patients with moderate to severe psoriasis who do not respond to conventional systemic treatments or for whom these therapies are contraindicated or intolerable.https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&volume=56&supp=1&Year=2022etanercepttnf-αpsoriasis |
| spellingShingle | Sibel Alper Etanercept Turkderm Turkish Archives of Dermatology and Venereology etanercept tnf-α psoriasis |
| title | Etanercept |
| title_full | Etanercept |
| title_fullStr | Etanercept |
| title_full_unstemmed | Etanercept |
| title_short | Etanercept |
| title_sort | etanercept |
| topic | etanercept tnf-α psoriasis |
| url | https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&volume=56&supp=1&Year=2022 |
| work_keys_str_mv | AT sibelalper etanercept |